Table 3.
Results from selected trials with EGFR-targeted therapies in patients with TNBC
| ClinicalTrials.gov identifier | Population | Therapy | Phase | Status |
|---|---|---|---|---|
| NCT00463788 | TNBC | Cetuximab + cisplatin | II | Completed, has results70 |
| NCT00232505 | TNBC | Cetuximab + carboplatin | II | Active, not recruiting71 |
| NCT01097642 | TNBC | Cetuximab + ixabepilone | II | Active, not recruiting72 |
| NCT02158507 | mTNBC | Veliparib + lapatinib | – | Recruiting73 |
| NCT01732276 | mTNBC | Gefitinib | II | Not yet recruiting74 |
| NCT00894504 | mTNBC | Gemcitabine + carboplatin + panitumumab | II | Completed, has results75 |
| NCT01426880 | TNBC | Carboplatin + NAC | II/III | Completed76 |
| NCT00540358 | mTNBC | Gemcitabine/carboplatin + iniparib | II | Completed77 |
Abbreviations: EGFR, epidermal growth factor receptor; NAC, neoadjuvant chemotherapy; TNBC, triple-negative breast cancer; mTNBC, metastatic TNBC.